United States Retinal Implants Market is estimated to reach US$ 118.17 million by 2031 | Top 3 key players - Bionic Vision Technologies, Vivani Medical, Inc., Samsara Vision Inc.

Market Size and Growth:

The Global Retinal Implants Market size was valued at US$ 59.78 million in 2022 and is estimated to reach US$ 118.17 million by 2031, growing at a CAGR of 9.1% during the forecast period (2024-2031). The Market is growing due to increasing prevalence of retinal disorders and advancements in implant technology improving vision restoration.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/retinal-implants-market?sz

The Retinal Implants Market involves the development, manufacturing, and commercialization of electronic devices designed to restore vision in patients with retinal degenerative diseases, such as retinitis pigmentosa and age-related macular degeneration. These implants convert visual information into electrical signals, stimulating retinal cells to improve sight. The market encompasses surgical devices, implantable chips, and supportive software systems for vision restoration.

Industry Recent Developments:

United States:

✅ July 2025: Launch of new AI-powered bionic limb prototypes by major U.S. medtech firms, focusing on personalized movement restoration and advanced vision restoration technologies, including retinal implants.

✅ September 2025: The smart retinal implants market in the U.S. is leading with a projected CAGR of 15.2% through 2035, driven by expanding aging population and increasing prevalence of retinal diseases.

✅ October 2025: U.S. retinal implants market valued at around USD 56.53 million in 2025, with forecasts suggesting growing demand due to technological advances in wireless implant systems and vision restoration applications.

Japan:

✅ July 2025: Japan shows strong market growth in retinal implants with projected CAGR of 14.4% through 2035, supported by precision medical technology and aging population needs.

✅ August 2025: The Japan bionic eye market, which includes retinal implants, is expected to grow significantly, driven by increasing retinal disease cases, advancements in microelectronics, AI-augmented image processing, and government push toward assistive technologies.

✅ September 2025: Japan's retinal implants segment focuses strongly on specialized and high-performance systems supported by advanced healthcare infrastructure and strong medical expertise, with a market size forecast to reach USD 53.2 million by 2035.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/retinal-implants-market?sz

Major 5 Key Players:

1. Bionic Vision Technologies
Bionic Vision Technologies has developed the BVT Bionic Eye System, the world's first suprachoroidal visual implant designed to restore functional vision to individuals suffering from inherited retinal diseases. The system delivers visual information to the brain, improving patients' awareness of external objects and surroundings. Recent initial human testing in seven patients demonstrated safety and efficacy, with positive outcomes in patient mobility and device stability.

2. Vivani Medical, Inc.
Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term, subdermal drug implants using its proprietary NanoPortalTM technology. These implants aim to deliver medication steadily over extended periods, addressing challenges associated with fluctuating drug delivery. Vivani's lead drug candidate, NPM-139, is under development for chronic weight management and type 2 diabetes.

3. Samsara Vision Inc.
Samsara Vision is a specialty medical device company focused on researching, developing, and manufacturing implantable ophthalmic devices to improve vision and quality of life for individuals with untreatable retinal disorders. Their lead product, the Implantable Miniature Telescope (IMT), is FDA-approved for monocular implantation to improve vision in patients with stable severe to profound vision impairment caused by bilateral central scotomas associated with end-stage age-related macular degeneration (AMD).

4. Visus Technology Inc.
Visus Technology is developing the Boston Retinal Implant Prosthesis, which uses a subretinal array of 16 electrodes that receives energy and data from an eyeglass-mounted video camera and radiofrequency coil. This system aims to restore vision in patients with retinal degenerative diseases.

5. Pixium Vision
Pixium Vision developed the PRIMA Bionic Vision System, a wireless retinal implant currently being studied in patients who have lost their sight due to outer retinal degeneration, such as atrophic dry age-related macular degeneration (AMD). The system aims to restore vision by converting light into electrical signals that stimulate the retina.

FDA Approvals and Regulatory Developments:

1. ENCELTO (Revakinagene Taroretcel-Lwey)
In March 2025, the FDA approved ENCELTO, the first implantable cell therapy for macular telangiectasia type 2 (MacTel), a rare retinal disease. This approval marks a milestone as the first authorized treatment for MacTel and the first cell-based neuroprotective treatment for any neurodegenerative retinal disease or central nervous system disorder.

2. PRIMA Retinal Implant
The PRIMA retinal implant, developed by Science Corporation, has shown promising results in clinical trials for patients with advanced age-related macular degeneration (AMD). The device, which works in conjunction with augmented reality glasses, has enabled patients to regain partial vision, including reading abilities. Regulatory approval is being pursued in the U.S. and Europe, with expectations for availability in Europe by 2026.

Mergers and Acquisitions:

1. Alcon's Acquisition of LumiThera
In September 2025, Alcon completed the acquisition of LumiThera, a company specializing in photobiomodulation therapy for dry AMD. The acquisition includes the Valeda PBM device, which demonstrated visual acuity improvement in clinical trials without serious adverse events. Alcon plans to expand Valeda PBM's availability to more markets by 2026, pending regulatory approvals.

2. Alcon's Agreement to Acquire STAAR Surgical
Alcon has agreed to acquire STAAR Surgical, known for its EVO family of lenses (EVO ICL) used in vision correction for patients with moderate to high myopia. The acquisition aims to enhance Alcon's portfolio in the vision correction segment.

3. Science Corporation's Acquisition of Pixium Vision's Prima Retinal Implants
Science Corporation acquired the intellectual property and related assets for Pixium Vision's Prima Retinal Implants. This acquisition positions Science Corporation to advance its brain-computer interface (BCI) technologies in the retinal implant space.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=retinal-implants-market

Segments Covered in the Retinal Implants Market:

1. By Product Type
Epiretinal Implants:
Implanted on the retina's surface, these devices stimulate the retinal ganglion cells to restore vision in patients with retinal degenerative diseases.

Subretinal Implants:
Placed beneath the retina, these implants directly interact with photoreceptor cells, offering more natural visual perception.

Other Types:
Includes retinal prostheses and experimental devices designed for specific retinal conditions.

2. By Application
Age-Related Macular Degeneration (AMD):
The largest application segment, as retinal implants help AMD patients regain partial vision.

Retinitis Pigmentosa:
A genetic disorder causing vision loss; retinal implants help stimulate remaining retinal cells.

Other Retinal Disorders:
Includes conditions like diabetic retinopathy or inherited retinal dystrophies.

3. By End User
Hospitals & Eye Clinics:
Major end-users due to the clinical setting required for implantation and follow-up.

Specialty Eye Centers:
Increasing adoption in private eye specialty clinics with advanced ophthalmology departments.

4. By Geography
North America:
High adoption due to advanced healthcare infrastructure and awareness.

Europe:
Growing investments in ophthalmic devices and favorable reimbursement policies.

Asia-Pacific:
Emerging market with increasing prevalence of retinal disorders and rising healthcare spending.

Rest of the World:
Includes Latin America, Middle East, and Africa, where adoption is gradually increasing.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Retinal Implants Market in 2025?
◆ What is the projected growth rate of the Retinal Implants Market through 2033?
◆ Who are the key players in the Retinal Implants Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.